The Food and Drug Administration on Friday approved Gilead Science's drug Hepsera (adefovir dipivoxil) for the treatment of hepatitis B. The drug was originally developed as a treatment for HIV disease but was rejected by the FDA in 1999 because of concerns over kidney toxicity at high doses. Hepsera is given at lower doses for the treatment of hepatitis B. The drug, a nucleotide reverse transcriptase inhibitor, works by blocking replication of the hepatitis B virus. It is administered once a day as a 10-milligram tablet and was immediately made available by Gilead upon FDA approval. Hepsera is the first medication to be approved by the federal agency for the treatment of chronic hepatitis B infection in more than five years and is one of only three treatments available.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














